Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Comment by HoldMeon Oct 16, 2020 1:09pm
154 Views
Post# 31729035

RE:My opinion: HUGE ERROR in listing on NEO

RE:My opinion: HUGE ERROR in listing on NEO Just my thinking is that the move to NEO vs the CSE isnt necessarily a better exchange and causing temporary issues with trading and quotes now but it gives QSC much higher exposure in the US by being able to distribute all the press releases to Americans.  That's a big deal.

However, those potential new US investors will find that they will have to go through the OTC Pinksheets to buy QSC stock and that to me isn't a desirable option.

I feel QSC should be trying to uplist the US side either to a higher version off the Pinksheets in the OTC as soon as possible.  

Lets all just hope that with more cubes rolling out, with sales to announce in the quarterly financials, being able to tell this story to US investors, that this will push our stock price higher.

MIght be putting the cart before the horse here, but if we can maintain a $5+ price [$4 USD], then maybe an uplist to the Nasdaq is in the plans!

JMO,

HM

<< Previous
Bullboard Posts
Next >>